Abstract Details
|
David Kreitzman, MD
(Parkinsons'S Disease and Movement Disorders Center of Long Island)
PRESENTER |
Dr. Kreitzman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acadia Pharmaceutical. Dr. Kreitzman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amneal. Dr. Kreitzman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cereval. Dr. Kreitzman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda Pharmaceutical. Dr. Kreitzman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Kreitzman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia Pharmaceutical. Dr. Kreitzman has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Acadia Pharmaceutical. Dr. Kreitzman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amneal Pharmaceutical. Dr. Kreitzman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin Pharmaceutical. Dr. Kreitzman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acorda Pharmaceutical. Dr. Kreitzman has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Neurocrine. Dr. Kreitzman has received research support from pharma 2b. Dr. Kreitzman has received research support from Neurocrine. Dr. Kreitzman has received research support from Addex. Dr. Kreitzman has received research support from Amneal. |
| Rohit Dhall, MD, FAAN (University of Arkansas for Medical Sciences) | Dr. Dhall has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Best Doctors Inc. Dr. Dhall has stock in Verve Therapeutics Inc. Dr. Dhall has stock in Roche Holding Limited. Dr. Dhall has stock in Enliven Therapeutics Inc. The institution of Dr. Dhall has received research support from Amneal. The institution of Dr. Dhall has received research support from Neuroderm. The institution of Dr. Dhall has received research support from Cerevel Therapeutics. The institution of Dr. Dhall has received research support from Neurocrine. The institution of Dr. Dhall has received research support from Neuraly. The institution of Dr. Dhall has received research support from SPARC. The institution of Dr. Dhall has received research support from Pharma2B. The institution of Dr. Dhall has received research support from Alexion. The institution of Dr. Dhall has received research support from Parkinsons Foundation. The institution of Dr. Dhall has received research support from UCB Pharma. The institution of Dr. Dhall has received research support from Inhibikase Therapeutics. The institution of Dr. Dhall has received research support from Amylyx Pharma. |
| Sherron H. Kell, MD (Impax Laboratories, Inc.) | No disclosure on file |
| No disclosure on file | |
| Suneel K. Gupta, PhD | No disclosure on file |